I've supported cell-based research and therapeutic manufacturing at Johnson & Johnson, Bristol Myers Squibb, WuXi AppTec, Drexel University, and Temple University. My work spans high-throughput screening cell culture, assay development support, and commercial CAR-T and tumor-infiltrating lymphocyte therapy manufacturing.
At Johnson & Johnson, I manage mammalian cell culture for high-throughput screening, including cell banking, cryopreservation, sterility coordination, inventory, and culture-condition optimization. I work closely with assay development scientists to deliver cells that meet performance and quantity targets.
In GMP manufacturing environments, I've investigated deviations, performed aseptic processing, supported cell selection and bioreactor workflows, and co-authored SOPs and batch records. At WuXi AppTec, I helped support Lifileucel's transition from clinical to commercial capacity and trained associates in aseptic and process-specific skills.
My research experience includes DAT inhibition assays, primary neuronal cultures, viral transfection, PCR, western blotting, confocal imaging, and microscopy data analysis. I'm also a co-author of a 2024 bioRxiv publication on neuroprotective inhibitors of acute axonal DLK palmitoylation.
